Characteristics of Treatment-experienced HIV-infected African Children and Adolescents Initiating Darunavir and/or Etravirine-based Antiretroviral Treatment.
PMID: 29140932
2018
The Pediatric infectious disease journal
Abstract: Forty seven patients (98.9%) had HIV genotype results: 41 (87.2%) had >=1 nucleos(t)ide reverse transcriptase inhibitor (NRTI)-resistance mutation (RM), predominantly M184V (76.6%; n = 36); 31 (65.9%) had >=1 non-NRTI-RM, including 27 (57.4%) with >=1 ETR-RM; 30 (63.8%) had >=3 protease inhibitor RM, including 20 (42.6%) with >=1 DRV-RM.
Paper-based detection of HIV-1 drug resistance using isothermal amplification and an oligonucleotide ligation assay.
Abstract: Finally, a lateral flow enzyme-linked immunosorbent assay (ELISA) differentiates between OLA-labeled products with or without M184V.
Abstract: The first step isothermally amplifies a section of HIV-1 reverse transcriptase containing M184V using a recombinase polymerase amplification (RPA) assay.
Abstract: This work presents a proof-of-concept assay to detect M184V, the most common drug resistance mutation after first-line antiretroviral therapy failure, in a paper format.
Result: Amplification is similar for both wild type and M184V HIV DNA, and a lower limit of 100 copies of target DNA is detectable via gel electrophoresis.
Figure: (B) Average SBRs of the lateral flow ELISA when varying copy numbers of DNA containing the PMID: 29253097
2018
Clinical infectious diseases
Abstract: Three participants with VF, had undetected plasma dolutegravir at >=1 time points; the M184V and R263R/K mutations developed in 1 participant.
Resistance to HIV Integrase Inhibitors: About R263K and E157Q Mutations.
Introduction: Their results showed that the presence of M184I or M184V with R263K further decreased viral infectiousness and replicative capacity compared to the effects of the individual mutations alone.
Introduction: assessed the impact of adding the M184I/V mutation to a R263K-mutated virus on viral replicative capacity.
HIV-1 with HBV-associated Q151M substitution in RT becomes highly susceptible to entecavir: structural insights into HBV-RT inhibition by entecavir.
Result: HIV-1 RT M184V was also detected from HIV-HBV co-infected patients receiving ETV monotherapy, and in vitro experiments further demonstrated that M184V of HIV-1 RT confers resistance to ETV.
Frequent cross-resistance to rilpivirine among subtype C HIV-1 from first-line antiretroviral therapy failures in South Africa.
Method: In total, 94 of 100 samples from patients failing ARV treatment also carried HIV-1 NRTI resistane mutations including M184V (82%), K65R (35%), L74I (19%), M41L (17%) or D67N (17%).
Transmission of HIV-1 drug resistance mutations within partner-pairs: A cross-sectional study of a primary HIV infection cohort.
Method: After one mixture (M184M/V) was identified in a recipient partner (PIC 90629), specimens from two later time points were evaluated to assess the intrahost dynamics of the M184V mutation over time and determine whether this mixture arose from a single transmitted variant and evolution in the recipient or from initial infection by two transmitted variants.
Result: At 52 and 61 days post-infection, 8 of 21 (38.1%) and 5 of 9 (55.6%) pol sequences from plasma contained the nonsynonymous M184V mutation, respectively.
Result: Longitudinal analysis of PIC90629 by SGA confirmed 454-pyrosequencing results and identified a mixture of M184M/V.
Result: The observed frequencies of M184M/V in PMID: 29589465
2018
AIDS research and human retroviruses
Abstract: Furthermore, major mutations, including M184V (2.2%) and Y188L (2.2%), were identified in the viral pol gene encoding reverse transcriptase derived from a study participant, suggesting that the prevalence of HIVDR is low in the region.
Impact of Antiretroviral Regimens on Cerebrospinal Fluid Viral Escape in a Prospective Multicohort Study of Antiretroviral Therapy-Experienced Human Immunodeficiency Virus-1-Infected Adults in the United States.
Abstract: Genotypic susceptibility score-adjusted central nervous system (CNS) penetration-effectiveness (CPE) values were calculated for CSF escape with M184V/I mutations (n = 34).
Abstract: Plasma and CSF M184V/I combined with thymidine-analog mutations were more frequent in CSF escape vs no escape (23% vs 2.3%).
Abstract: Reduced CNS ART bioavailability may predispose to CSF escape in patients with M184V/I mutations.
Discussion: Analyses in this study suggest that individuals on PI-based regimens are at elevated risk for CSF escape, and that risk may extend to individuals with historic M184V/I mutations and CSF accumulation of major DRMs.
Discussion: However, when resistance mutations were factored into CPE values among participants with common
Rare emergence of drug resistance in HIV-1 treatment-naive patients receiving elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide for 144 weeks.
Abstract: M184V/I was the most prevalent RAM (1.2% overall).
Abstract: Resistant virus emerged in 24 patients who developed resistance to antiretrovirals in the regimens (E/C/F/TAF: M184V/I [1.3%], INSTI-RAMs [0.9%], K65R/N [0.2%]; E/C/F/TDF: M184V/I [1.0%], INSTI-RAMs [0.9%], K65R/N [0.5%]).
HIV mutation literature information.
PMID: 
2018
The Pediatric infectious disease journal
Browser Board
Co-occurred Entities
Filtrator
ViMRT